RxSight, Inc. (RXST) Stock

Understand RxSight, Inc.: how it makes money

RxSight makes light-adjustable intraocular lenses for cataract surgery and the office-based UV light devices doctors use to fine-tune a patient's vision post-op; it earns from selling lenses (recurring) and capital equipment. The installed base of light delivery devices is the platform from which lens volume is meant to compound, so the core question is utilization per device over time.

Each placed light delivery device is a captive channel for recurring lens sales; the business profits when physicians raise treatment volume per installed unit rather than adding new devices, making the device base the true leading indicator of revenue.

Business quality (Weak): A 76% gross margin signals genuine pricing power on the lens, but the company is still burning heavily (operating margin around -58%) while revenue contracts, so the installed-base growth story has not yet translated to a self-funding operation.

Bull case

• Alcon deal funds the runway: The Alcon collaboration brings non-dilutive capital, milestone payments, and potential long-term royalties, directly easing the operating cash burn (operating margin around -58%) while the company works to rebuild volume.
• No utilization ceiling yet: Management reported that physicians it consulted showed no sign of a utilization ceiling, and the installed base offers a platform for deeper per-doctor engagement, meaning lens volume per device still has meaningful headroom to grow.

Bear case

• Lens volumes are falling: Core product sales and LAL volumes declined materially year over year, which directly undermines the installed-base compounding narrative and raises the question of whether per-device utilization has peaked.
• Margin already under pressure: Gross margin slipped to 71.2% in the quarter because slower inventory flow-through pushed up inventory-related costs, narrowing the buffer the business has while it operates at a -58% operating margin.
• No guidance to anchor the story: The company withdrew its forward guidance, removing the primary reference point investors need to model the revenue and operating recovery timeline, which widens the uncertainty premium on the stock.

RxSight, Inc. earnings call transcripts

• RXST Q2 FY26 earnings call transcript (reported 2026-08-05) · analysis

All RXST earnings calls

Related Companies (Medical Equipment; 8 comparable device makers)

• STAAR Surgical Company (STAA)
• Xtant Medical Holdings, Inc. (XTNT)
• Quanterix Corporation (QTRX)
• InfuSystem Holdings, Inc. (INFU)
• Neuronetics, Inc. (STIM)
• Outset Medical, Inc. (OM)
• OraSure Technologies, Inc. (OSUR)
• Pacific Biosciences of California, Inc. (PACB)